Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study
BMJ 2020; 370 DOI: https://doi.org/10.1136/bmj.m3342 (Published 23 September 2020) Kristian B Filion, Lisa M Lix, Oriana HY Yu, Sophie Dell’Aniello, Antonios Douros, Baiju R Shah, Audray St-Jean, Anat Fisher, Eric Tremblay, Shawn C Bugden, Silvia Alessi-Severini, Paul E Ronksley, Nianping Hu, Colin R Dormuth, Pierre Ernst, Samy Suissa, on behalf of the Canadian Network for Observational Drug … [Read more...]
[127] Audit and Feedback: Personal Prescribing Portrait
Primary care prescribers who treat a wide variety of conditions in community-dwelling patients require broad prescribing knowledge.1,2 The number of existing drug options and new drugs available each year has created a challenging work environment. There is a corresponding need to find innovative methods to help community-based physicians monitor and evaluate the appropriateness of their … [Read more...]
[126] Serious harms with long-term PPI use in older adults
Proton pump inhibitors (PPIs) were introduced in 1988. Health Canada, professional, and academic groups all agree that they should be prescribed at the lowest dose and for the shortest duration appropriate to the condition treated. However, PPI use continues to expand. Between 2000 and 2018 BC’s population grew by 20%, but use of PPIs increased by 257%. In 2018, 442,559 British Columbians (9% of … [Read more...]
Sodium–Glucose Cotransporter 2 Inhibitors and the Risk of Below-Knee Amputation: A Multicenter Observational Study
Diabetes Care Aug 2020, dc200267; DOI: 10.2337/dc20-0267 Oriana Hoi Yun Yu, Sophie Dell’Aniello, Baiju R. Shah, Vanessa C. Brunetti, Jean-Marc Daigle, MichaelFralick, Antonios Douros, Nianping Hu, Silvia Alessi-Severini, Anat Fisher, Shawn C. Bugden, Paul E.Ronksley, Kristian B. Filion, Pierre Ernst, Lisa M. Lix for the Canadian Network for Observational Drug Effect Studies (CNODES) … [Read more...]
[Sep 23] Careful and Kind Diabetes Care
TI Best Evidence Webinar PRESENTER: Dr. Victor Montori, MD is a Professor of Medicine at Mayo Clinic. An endocrinologist and health services researcher, Dr. Montori is the author of more than 650 peer-reviewed publications and is among the top 1% of researchers with most cited papers in clinical medicine and in social science worldwide in the last decade. He serves in the Editorial Advisory Board … [Read more...]
[Sep 16] TI Best Evidence Webinar: “We” Should Really Stop that PPI, eh?
TI Best Evidence Webinar “We” Should Really Stop that PPI, eh? PRESENTERS: Dr. Carolyn Bubbar & Hafeez Dossa DATE: Wednesday, September 16th 2020 TIME: 12:00 noon - 13:15 Pacific Daylight Time PDT [UTC -7 convert to your local time] CME CREDITS: MainPro+/MOC Section 1 credits: 1.0. You must register, attend the webinar and complete the evaluation in order to receive your … [Read more...]
[Sep 9] COVID19: Finding a Treatment That Works
TI Best Evidence Webinar This event has already taken place. Scroll down to view a video recording of the event. PRESENTER: Dr. Srinivas Murthy, MD. TOPIC: COVID19: Finding a Treatment That Works DATE: Wednesday, September 9, 2020 TIME: 19:00 - 20:15 Pacific Daylight Time [UTC -7: convert to your local time] AUDIENCE: Clinicians, health professionals, researchers, and … [Read more...]
Therapeutics Initiative Webinars coming to you in September
… [Read more...]
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis
Annals of Internal Medicine 2020 July 28. DOI: 10.7326/M20-0289 Antonios Douros, MD, PhD; Lisa M. Lix, PhD; Michael Fralick, MD, PhD; Sophie Dell’Aniello, MSc; Baiju R. Shah, MD, PhD; Paul E. Ronksley, PhD; Eric Tremblay, BPharm, MSc; Nianping Hu, PhD; Silvia Alessi-Severini, PhD; Anat Fisher, MD, PhD; Shawn C. Bugden, PharmD, MSc; Pierre Ernst, MD, MSc; and Kristian B. Filion, PhD; for the … [Read more...]
[125] Can prescribers avoid contributing to opioid use disorder?
Case vignette: A 21 y/o has surgery for a condition expected to improve. He fills a discharge prescription for 5 days of an opioid at a standard dose. At 1-week follow-up with his family doctor for suture removal, he describes ongoing pain. Is a renewal of opioid appropriate, potentially dangerous, or both? Aggressive promotion of opioids for chronic non-cancer pain (CNCP) began in the … [Read more...]
- 1
- 2
- 3
- …
- 29
- Next Page »
